Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepotinib for metastatic non-small cell lung cancer with MET exon 14 skipping mutations
ACTRN12621000811808Phase 2Completed
- Sponsor
- The University of Sydney
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tepotinib, sponsored by The University of Sydney. Started Nov 2021; status: completed.
02
Drugs
tepotinib
Beyond the preview
Go deeper on ACTRN12621000811808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000811808.